TerminatedPhase 1NCT03162562
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CanariaBio Inc.
- Principal Investigator
- Christopher Nicodemus, MD FACPAIT Strategies
- Intervention
- Oregovomab(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 18-90 years · FEMALE
- Timeline
- 2017 – 2020
Study locations (2)
- Florida Hospital Cancer Institute, Orlando, Florida, United States
- VCU Massey Cancer Center, Dalton Oncology Clinic, Richmond, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03162562 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06268665Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced NeuropathyUniversity of California, Davis
- RECRUITINGNANCT05937620Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian CancerFundacion Clinic per a la Recerca Biomédica
- RECRUITINGNANCT06061874Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal CarcinomatosisJules Bordet Institute
- RECRUITINGNANCT05457595Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological MalignanciesCNAO National Center of Oncological Hadrontherapy
- ACTIVE NOT RECRUITINGPHASE3NCT01376752Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer TreatmentUNICANCER